NY-ALVAREZ-&-MARSAL
18.1.2023 07:01:35 CET | Business Wire | Press release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 85 professionals across Brazil, Benelux, Canada, Cayman Islands, China, France, Germany, India, Spain, United Arab Emirates, United Kingdom and the United States, to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their commitment to help clients maximize value and drive change amid ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. Their proven ability to help solve for clients’ complex problems is critical to the firm’s success and growth moving forward.”
Henry Chambers, Hong Kong
Eden Chen, Shanghai
Sally Sun, Hong Kong
Pedro Bortolotto, São Paulo
Marcelo Compte, São Paulo
Rodrigo Domingues, São Paulo
Lilian Giorgi, São Paulo
Rodrigo Hong, São Paulo
Henrique Kanashiro, São Paulo
Rafael Mendonca Rodrigues, São Paulo
Fabio Missiato, São Paulo
Corporate Performance Improvement
Tiffany Guthrie, Houston
Mike Hall, San Francisco
John McKinnis, Dallas
Sam Rudkin, Atlanta
Kenneth Cochran, Charlotte
Jeffrey Dwyer, Chicago
Lakshman Lakshmanan, Dallas
Chad Lusk, Chicago
Joanna Rangarajan, New York
Global Disputes and Investigations
Lee Betteridge, London
Gary Foster, London
EMEA – Performance Improvement
Private Equity Performance Improvement
Nicola Barbini, London
Chris Gobby, London
Britta Mittler, Frankfurt
Till Prinz, Dusseldorf
Tim Veen, Munich
Gerardo Villalba Bello, Madrid
Ysabel Gaspar Zayco, London
Robert Bradbury, London
Dominic Roope, London
Jatin Arora, Dubai
Mark Bennett, Paris
Daran Hopper, London
Dirk Naujokat, Munich
Steve Trainor, London
Diana Wong, London
EMEA Restructuring
Barry Lynch, Grand Cayman
Helen Skeates, London
David Johnston, London
José Miguel Gómez Rivas, Madrid
Bill Ozturk, Dubai
Environmental, Social and Governance (ESG)
Stephanie Weiler, Chicago
JoyAnn Book, Phoenix
Bianca A. Briola Charlotte
David Nidetz, Detroit
Rich Rieger, Chicago
Anup Gandhi, Mumbai
Pranav Sheth, Mumbai
Infrastructure & Capital Projects
Sue Frost, Washington, D.C.
Alan Richard, Washington, D.C.
Private Equity Performance Group
Kent Edgerton, Nashville
Jana Gold, Washington, D.C.
Brad Howard, New York
Larry Thomas, Tampa
Klaus Weisenberger, San Francisco
Daniel Harlan, Washington, D.C
Restructuring & Turnaround (North America)
Taylor Atwood, Dallas
Matthew Davidson, Detroit
Chad Ellison, Calgary
Kamila Khairoullina, New York
Mark Sidorenkov, Phoenix
Jeff Sielinski, Detroit
Michael Zembillas, Atlanta
Simon Bernstein, New York
Stephanie Doughty, Houston
Michael Farkas, New York
Simon Gore, London
Jack Hollyman, London
Jac Emilio Martinez, Miami
Joseph Plati, New York
Brendan Sinnott, New York
Katya Umanskaya, Los Angeles
Global Transaction Advisory Group
Anuj Astir, New York
Nout Brugman, Amsterdam
David Cho, Chicago
Vitor Garcia, Sao Paulo
Jimmy Glenn, Atlanta
Nick Lynch, London
Jai Tandan, Mumbai
Rhett Taylor, Nashville
Nick Thoele, New York
Cedric Zana, Paris
Cole Corbin, New York
Steven Fischoff, Chicago
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 7,000 people across five continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com. Follow A&M on LinkedIn, Twitter, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom